Inflammatory Disease
Shorts
Podcasts
Continuing Medical Education
All News
Advertisement
In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.
Clinical outcomes improved in both switch directions following treatment modification, with substantial reductions in PASI and EASI scores.
Strong clinical observation and knowledge of disease variants are essential when advanced diagnostics are unavailable.
This review of the latest dermatological studies includes insights on familial HS comorbidities, localized HA acne patch therapy, profiles of dyshidrotic eczema patients, and more.
Resource-poor environments exist not only globally but also in everyday settings like nursing homes, prisons, foster care, and low-income households.
Researchers reported that patients with more extensive HS disease involvement experienced significantly greater financial strain.
In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.
Can a Mediterranean diet clear skin, or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.
In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.
Advertisement
In the pivotal trials, dupilumab significantly reduced itch severity and urticaria activity at week 24 and increased rates of well-controlled disease and complete response compared with placebo.
In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.
Affecting up to 25% of children worldwide, pediatric AD carries a significant quality of life burden that extends to caregivers.
The biologic is the first of its kind approved for young children with antihistamine-refractory CSU, expanding an existing indication that previously covered adults and adolescents.
This review of the latest dermatological studies includes insights on minoxidil in onychodystrophy, teleheath outcomes in HS patients, pediatric AD referrals, and more.
AI-analyzed EHRs show a surging burden of hidradenitis suppurativa, chronic urticaria, psoriasis, and eczema, with major comorbidities, costly care, and low biologic use.
In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.
Emerging acne therapies like narrow-spectrum antibiotics, hormonal agents, and immunomodulators are promising, more personalized alternatives to isotretinoin, according to new research.
Renata Block, DMSc, MMS, PA-C, and Jamie Restivo, MPAS, PA-C, explore how hypochlorous acid sprays and sodium hypochlorite washes simplify AD adjunct care, improving adherence, antimicrobial control, and symptom relief.
New top-line results from the BE BOLD trial provide dermatology clinicians with comparative data on 2 biologic therapies targeting different inflammatory pathways in psoriatic arthritis (PsA).
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Jessica DeLuise, PA-C, MHS, CCMS, joins Derm Dispatch to discuss how nutrition and lifestyle intersect with inflammatory skin disease across clinical settings.
Dermatology Times recently concluded its second annual Horizons in Advanced Practice meeting in Tampa, Florida, featuring nurse practitioners and physician assistants from across the country.
HS is frequently misdiagnosed for 7 to 10 years because its symptoms resemble conditions like inflamed epidermal cysts, nodulocystic acne, and furuncles.
In the latest Cutaneous Connection podcast episode, Renata Block, DMSc, MMS, PA-C, and patient advocate Suki Tipp discuss the clinical, emotional, and financial toll of delayed diagnosis of indolent systemic mastocytosis.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!
Explore the potential of glucagon-like peptide-1 (GLP-1) therapies in dermatology, including inflammatory skin diseases such as psoriasis and hidradenitis suppurativa, to improve patient outcomes.
Recludix Pharma has initiated clinical trials for REX-8756, a promising oral STAT6 inhibitor targeting inflammatory diseases, marking a significant milestone in treatment innovation.
At the Dermatology Times Horizons in Advanced Practice meeting in Tampa, Florida, conference chair Lakshi Aldredge, MSN, ANP-BC, DCNP, focused a discussion on efficacy data for adalimumab, secukinumab, and bimekizumab.
Izabela Horzempa, PA-C, analyzes the challenges of chronic hand eczema (CHE) and shares innovative treatment options that enhance patient quality of life and management strategies.
Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed the 3 latest non-steroidal topicals for atopic dermatitis at the Horizons in Advanced Practice meeting.
Lakshi Aldredge, MSN, ANP-BC, DCNP, discussed key symptoms of CHE, the function of the JAK-STAT pathway, and key data from the DELTA trials evaluating delgocitinib cream at the Horizons in Advanced Practice meeting.
Maui Derm NP+PA Fall 2025 conference showcases cutting-edge insights in dermatology, featuring expert discussions on skin cancer, atopic dermatitis, and rare dermatoses.
Explore the latest advancements and expert insights from the SDPA Fall 2025 Meeting held in San Antonio, Texas.
New data presented at Fall Clinical 2025 reveal that patients in socioeconomically disadvantaged areas are significantly less likely to initiate biologic or small molecule treatments.
Selective JAK1 inhibition with upadacitinib may offer a fast-acting, steroid-sparing option for refractory lichen amyloidosis by interrupting IL-31–mediated itch and the itch–scratch cycle.
Rural patients face critical delays in dermatology care, highlighting the urgent need for expanded access and support for NPs and PAs in underserved areas.
A poster at Maui Derm NP+PA Fall shows trifarotene cream's promise in treating acne and post-inflammatory hyperpigmentation in diverse patients, enhancing skin health and appearance.
In the latest Cutaneous Connection podcast episode, Renata Block, DMSc, MMS, PA-C, and Isabelle Thibau, MPH, discuss the National Eczema Association's EczemaWise app and how it can be used by both clinicians and patients.
Although bimekizumab carries a precaution for suicidal ideation and behavior, current data suggest it may improve mental health outcomes for patients with psoriasis.
CD19 CAR T-cell therapy may modulate immune dysregulation in underlying diseases such as psoriasis.
Hidradenitis suppurativa requires clinical vigilance, empathy, and the courage to escalate therapy early.
Read more about acne treatment tips shared at the 2024 SDPA Fall Conference by experts such as Shanna Miranti, MPAS, PA-C, and Hilary Baldwin, MD.
4 case histories highlight the physical and psychosocial burden of generalized pustular psoriasis.
An 82-year-old woman with PPP and treated with roflumilast cream 0.3% achieved complete clearance after 5 weeks of treatment.
Understanding comorbidities such as thyroid dysfunction and vitiligo helps to navigate comprehensive care to achieve long-lasting results in alopecia areata treatment.
Explore how surveyed providers perceive current and emerging therapies in the atopic dermatitis.
The increasing prevalence of this chronic condition in children necessitates understanding its broader impacts and management strategies.
“Edward” is a 35-year-old Hispanic male presenting with a new rash on the buttocks which has been present for approximately 1 month.
With the latest advancements in dermatology, there is a great range of treatments available to address the various types of acne scarring.
Learn more about the proven strategies to keep your pediatric patients' skin healthy and allergy-free.
Blackburn presented integrative medicine pearls on gut and hormone health at the 2024 Diversity in Dermatology meeting.
Over 50% of women in their 20s and over 35% of women aged 30 to 39 years struggle with adult female cystic acne.
As someone who practices dermatology, it can often be difficult to determine if any of these new skin care trends are efficacious.
Biologics represent the pinnacle of scientific progress, engineered to precisely target conditions previously deemed untreatable. However, any dermatology provider who has prescribed one quickly learns of the immense barriers surrounding them.
When examining Ezra’s skin, you note well-defined erythematous scaly plaques with well-defined, serpiginous, raised borders and yellow crusting on the anterior shins and forearms.
Systemic corticosteroids are often used as primary therapy for PG, but alternatives should be considered for their favorable safety profile.
Half of study participants achieved treatment success vs less than one-fourth with vehicle.
Dupilumab’s efficacy was sustained through the 260-week open-label study.
From bug bites to poison ivy, the skin can be exposed to a large spectrum of trouble while patients spend extended time outside.
The American Skin Association estimated that 50 million Americans are exposed to urushiol yearly, the most common contact allergen in the US.
Click here to answer this week's HS poll.
Melodie Young, MSN, ANP-c, shares pearls on why prioritizing skin checks during Psoriasis Action Month in August is critical.
In a Maui Derm NP+PA Summer poster presentation, investigators revealed that treatment with spesolimab resulted in a reduction of lesions.
Researchers evaluated factors affecting quality of life and what to consider when determining a patient’s psoriasis treatment plan.
Block spoke to the founder of the Eczema Sample Store over Instagram Live to bring more awareness to the company’s mission.
The gut-brain-skin axis is more important to overall health than previously understood, and prebiotics and probiotics play a large role in the benefits.
Jodi Westfall, NP, explains how she improves common skin conditions traditionally and from a metabolic perspective.
The management of oily and acne-prone skin remains a challenge for both patients and dermatology professionals.
Atopic dermatitis is not a "one-size-fits-all" condition.
Cynthia J. Trickett, PA-C, MPAS, discusses the personal and clinical effects of atopic dermatitis in adult and pediatric patients at the Maui Derm NP+PA 2022 Summer Conference in Colorado Springs, Colorado.
In part two of her presentation at the 2022 SDPA Annual Summer Meeting, Shanna M. Miranti, MPAS, PA-C, discusses the best treatment regimen for your rosacea patients.
Shanna M. Miranti, MPAS, PA-C, details how to determine which medications, products, and overall regimen will work for your acne patients.
Advertisement
Advertisement
Trending on Dermatology Times
1
Single-Dose IL-2 Fusion Protein Shows Hair Regrowth Signal in Early Trial
2
Study Finds Psoriasis Patients Trust Topical Therapies Less Than Those With AD
3
Stapokibart Successfully Treats Refractory CSU After Omalizumab Failure in New Case Report
4
Oral STAT6 Degrader KT-621 Delivers Biologics-Like Efficacy in Moderate to Severe AD
5